Merck’s Vioxx Settlement Gets Mixed Reception From Plaintiffs Lawyers
Executive Summary
Two months after Merck inked a deal to settle the bulk of Vioxx product liability litigation, the pharmaceutical industry is riveted on the outcome of the agreement
You may also be interested in...
Merck’s Novel Vioxx Settlement May Set Standard To Resolve Litigation
Merck crafted extraordinary terms in its $4.85 billion agreement to resolve the bulk of Vioxx litigation, which analysts are heralding as a good result for the company
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.